- Home
- LMFA vs BTAI Comparison
LMFA vs BTAI Comparison
Compare LMFA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMFA
- BTAI
- Stock Information
- Founded
- LMFA 2008
- BTAI 2017
- Country
- LMFA United States
- BTAI United States
- Employees
- LMFA N/A
- BTAI N/A
- Industry
- LMFA Finance: Consumer Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- LMFA Finance
- BTAI Health Care
- Exchange
- LMFA Nasdaq
- BTAI Nasdaq
- Market Cap
- LMFA 8.6M
- BTAI 8.3M
- IPO Year
- LMFA 2015
- BTAI 2018
- Fundamental
- Price
- LMFA $2.86
- BTAI $1.79
- Analyst Decision
- LMFA Hold
- BTAI Buy
- Analyst Count
- LMFA 1
- BTAI 5
- Target Price
- LMFA N/A
- BTAI $34.60
- AVG Volume (30 Days)
- LMFA 105.5K
- BTAI 291.8K
- Earning Date
- LMFA 08-13-2025
- BTAI 08-05-2025
- Dividend Yield
- LMFA N/A
- BTAI N/A
- EPS Growth
- LMFA N/A
- BTAI N/A
- EPS
- LMFA N/A
- BTAI N/A
- Revenue
- LMFA $8,029,601.00
- BTAI $1,852,000.00
- Revenue This Year
- LMFA $0.98
- BTAI $5.03
- Revenue Next Year
- LMFA $4.31
- BTAI $291.01
- P/E Ratio
- LMFA N/A
- BTAI N/A
- Revenue Growth
- LMFA N/A
- BTAI 5.47
- 52 Week Low
- LMFA $1.02
- BTAI $1.17
- 52 Week High
- LMFA $5.35
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- LMFA 76.89
- BTAI 62.90
- Support Level
- LMFA $2.18
- BTAI $1.59
- Resistance Level
- LMFA $2.46
- BTAI $2.22
- Average True Range (ATR)
- LMFA 0.21
- BTAI 0.21
- MACD
- LMFA 0.09
- BTAI 0.04
- Stochastic Oscillator
- LMFA 97.64
- BTAI 75.00
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.